Evaluation of 89Zr-TLX250 PET/CT in Chinese Patients With Indeterminate Renal Masses or Suspected Recurrent Renal Clear Cell Carcinoma
- Status
- COMPLETED
- Phase
- PHASE1
Clinical Trials Related to Clear Cell Renal Cell Carcinoma
Related studies linked through entity extraction aliases.
A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
A Small-molecule Carbonic Anhydrase IX Targeting PET Tracer in Clear Cell Renal Cell Carcinoma
- Status
- COMPLETED
- Phase
- EARLY_PHASE1
Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
- Status
- RECRUITING
- Phase
- PHASE1
68Ga-P16-093 and 18F-FDG PET/CT Imaging in the Same Group of Clear Cell Renal Cell Carcinoma Patients
- Status
- COMPLETED
- Phase
- NA
Seleno-L Methionine (SLM)-Axitinib-Pembrolizumab
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Microbiota Transplant to Cancer Patients Who Have Failed Immunotherapy Using Faeces From Clinical Responders
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study of Nivolumab in Combination With 177Lu-girentuximab for Kidney Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Novel Biomarkers of Hypoxia and Metabolism in Clear Cell Renal Cell Carcinoma
- Status
- RECRUITING
- Phase
- N/A
A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)
- Status
- TERMINATED
- Phase
- PHASE1
A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
A Beta-only IL-2 ImmunoTherapY Study
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Pembrolizumab and Axitinib as Neoadjuvant Therapy for Locally Advanced Non-metastatic Clear Cell Renal Cell Carcinoma
- Status
- UNKNOWN
- Phase
- PHASE2
[18F]PT2385 PET/CT in Patients With Renal Cell Carcinoma
- Status
- RECRUITING
- Phase
- PHASE1
A Study of Sintilimab in Combination With Axitinib in Advanced Renal Cell Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3